Page 2423 - Williams Hematology ( PDFDrive )

2394 Index Index 2395

Activated protein C (APC) resistance, 1955, relapse, 1518 Acute myeloblastic leukemia, 1382f, 1387, 1388t
2222, 2224t, 2268. See also Factor V treatment sequelae, 1519–1520 Acute myelofibrosis, 1392
Leiden/factor V G1691A definition and history, 1505–1506 Acute myelogenous (myeloid) leukemia
Activated prothrombin complex concentrate, development in utero, 1507 (AML), 1373–1415
2185 differential diagnosis, 1513–1514 cell metabolism in, 197–198
Activation-induced deaminase (AID), 1169, disseminated intravascular coagulation classification, 1279–1280, 1380, 1380t
1213, 1214t, 1215, 1710 and, 2208 clinical features, 1380–1381
Activator protein 1 (AP1), 1606 early T-cell precursor, 1512, 1512t extramedullary tumors, 1285
Activator protein 3 (AP3) complex, 1843 etiology and pathogenesis, 1506–1508 hyperleukocytic syndromes, 1285–1286,
Activin A, 1713, 1738 cell-cycle defects, 217 1286t, 1384
Acute basophilic leukemia, 1389t, 1393 chromosomal abnormalities, 177f, 183, marrow necrosis, 1287, 1385
Acute chest syndrome, 768–769, 769f 184t, 186, 186f, 1508t, 1513t metabolic signs, 1286–1287
Acute coronary syndrome (ACS), 2295. See gene mutations, 166, 1506–1507, myeloid sarcoma, 1379
also Myocardial infarction (MI) 1507–1508, 1508t, 1513t. procoagulant and fibrinolytic activator
Acute eosinophilic leukemia, 955t, 1389t, See also ETV6-RUNX1, in acute release, 1285
1392 lymphoblastic leukemia signs and symptoms, 1380
Acute erythroid leukemia, 608, 1382f, 1389t, incidence, 1506, 1506f specific organ system involvement,
1390 risk factors, 1506–1507 1379–1380
Acute fatty liver of pregnancy, 2012, 2211 flow cytometry, 36f splenomegaly, 1287
Acute graft-versus-host disease. See Graft- laboratory features, 1509–1513, 1510t systemic symptoms, 1286
versus-host disease (GVHD) blood, 1509–1510, 1509t clonal myeloid disease transition and,
Acute hemolytic transfusion reaction, cerebrospinal fluid examination, 1510, 1280–1281
2374–2375 1510t course and prognosis, 1411–1415
Acute infection lymphocytosis, 1202, 1203f chest radiography, 1509f, 1510 clonal remissions, 1411–1412
Acute inflammation. See Inflammatory genetic classification, 1512–1513, 1513t detection of minimal residual disease,
response, acute immunologic classification, 1511–1512, 1412–1415
Acute intermittent porphyria (AIP), 889, 1512t factors influencing, 1412, 1413–1414t
900–904 marrow, 1510–1511, 1510t genetic abnormalities and, 220–221t,
clinical features, 890t, 902 morphologic and cytochemical analysis, 363, 1411t
definition and history, 900–901 1511, 1511f long-term survival, 1412, 1412t
diagnosis, 903–904 Philadelphia chromosome-negative, 364 after relapse, 363–364
drugs and, 901, 902t Philadelphia chromosome-positive, 183, remission-relapse pattern, 1284, 1284f
enzymes affected by, 890t, 891f 364, 1517, 1521 spontaneous remissions, 1412
laboratory features, 891t, 903f platelet function and, 2082 treatment results, 1411–1412
pathogenesis of clinical findings, 901–902 T-cell. See T-cell acute lymphoblastic definition and history, 1373–1374
pathophysiology, 901 leukemia (T-ALL) differential diagnosis, 1393
precipitating factors, 901 therapy, 1514–1518 disseminated intravascular coagulation
therapy, 904 central nervous system, 1517 and, 2208
Acute iron poisoning, 638–639 continuation, 1516–1517 epidemiology, 1379–1380
Acute liver failure, 2193. See also Hepatic hematopoietic cell transplantation, 364, essential thrombocythemia and, 1310
disease/dysfunction 1517–1518 etiology and pathogenesis, 1374–1380
Acute lymphoblastic (lymphocytic) leukemia history of, 197 chromosomal abnormalities, 180–182,
(ALL), 1505–1521 intensification (consolidation), 1516 225, 1383
aplastic anemia and, 520 investigational therapies, 415 in chromosomes 5 and 7, 1383, 1384t
B-cell. See B-cell acute lymphoblastic remission induction, 1515 deletions, 177f, 179t, 1384t
leukemia (B-ALL) supportive care, 1514–1515 frequency, 182f
cell metabolism in, 197–198 targeted, 1518 inversions, 179t, 180–181, 220t, 1384t
chronic myelogenous leukemia transient myeloproliferative disorder and, prognosis and, 1280, 1413–1414t
transformation to, 1465–1466 1385–1386 t(8;21), 180, 220t, 1383, 1384t, 1415
clinical features, 1508–1509, 1509t Acute mast cell leukemia, 1389t, 1393 t(15;17), 181, 220t, 1280, 1383, 1384t,
physical findings, 1509, 1509f Acute megakaryoblastic (megakaryocytic) 1415
signs and symptoms, 1508–1509 leukemia, 1382f, 1389t, 1392 t(16;16), 180–181, 220t
course and prognosis, 1518–1521 Acute megaloblastic anemia, 604–605 translocations, 177f, 179t, 1280,
event-free survival, 1505–1506, 1506f, Acute monocytic leukemia, 181, 1096, 1382f, 1384t, 2388
1513t 1388t, 1391–1392 translocations involving 11q, 181,
indicators of, 183, 1520–1521, 1521t Acute mountain sickness, 881 220t

Kaushansky_index_p2393-2506.indd 2394 9/21/15 3:21 PM